- Home
- SLN vs TCMD Comparison
SLN vs TCMD Comparison
Compare SLN & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- TCMD
- Stock Information
- Founded
- SLN 1994
- TCMD 1995
- Country
- SLN United Kingdom
- TCMD United States
- Employees
- SLN N/A
- TCMD N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- TCMD Medical/Dental Instruments
- Sector
- SLN Health Care
- TCMD Health Care
- Exchange
- SLN Nasdaq
- TCMD Nasdaq
- Market Cap
- SLN 268.8M
- TCMD 300.1M
- IPO Year
- SLN N/A
- TCMD 2016
- Fundamental
- Price
- SLN $6.59
- TCMD $14.69
- Analyst Decision
- SLN Buy
- TCMD Buy
- Analyst Count
- SLN 6
- TCMD 4
- Target Price
- SLN $39.67
- TCMD $16.83
- AVG Volume (30 Days)
- SLN 115.5K
- TCMD 180.9K
- Earning Date
- SLN 11-13-2025
- TCMD 11-03-2025
- Dividend Yield
- SLN N/A
- TCMD N/A
- EPS Growth
- SLN N/A
- TCMD N/A
- EPS
- SLN N/A
- TCMD 0.63
- Revenue
- SLN $27,169,000.00
- TCMD $298,851,000.00
- Revenue This Year
- SLN N/A
- TCMD $8.78
- Revenue Next Year
- SLN N/A
- TCMD $8.49
- P/E Ratio
- SLN N/A
- TCMD $23.35
- Revenue Growth
- SLN 22.28
- TCMD 6.15
- 52 Week Low
- SLN $1.97
- TCMD $8.61
- 52 Week High
- SLN $19.36
- TCMD $21.10
- Technical
- Relative Strength Index (RSI)
- SLN 69.56
- TCMD 60.80
- Support Level
- SLN $5.00
- TCMD $14.00
- Resistance Level
- SLN $5.83
- TCMD $14.99
- Average True Range (ATR)
- SLN 0.41
- TCMD 0.44
- MACD
- SLN 0.16
- TCMD -0.04
- Stochastic Oscillator
- SLN 93.42
- TCMD 60.50
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.